HeraGen Injection

Adult dosage

Generally, 500 mL is administered via slow intravenous infusion. The administration rate is typically based on 180 minutes for 500 mL in adults. For central venous administration, mix 500 mL of this medication with dextrose solutions, and administer continuously into the central vein over 24 hours. Adjustments should be made according to age, symptoms, and body weight.

This medication must be used according to the instructions of a physician. It should not be administered to patients with severe renal impairment or high blood urea nitrogen levels. Patients with abnormalities in amino acid metabolism beyond liver dysfunction should also avoid its use. It is safer not to administer it to patients with metabolic disorders involving nitrogen utilization, severe heart failure, or pulmonary edema. Patients with very low or absent urine output and those with high sodium or chloride levels should not use this medication. If magnesium is present, it should not be given to patients with heart block or severe myasthenia gravis, and caution is needed for patients with fluid overload. Caution should be exercised in administering it to patients with severe acidosis, heart failure, edema due to sodium retention, or hyperkalemia. Sodium bisulfite included in this medication can cause allergic reactions, especially in asthma patients, potentially triggering asthma attacks. Occasionally, symptoms related to the heart such as skin rash, nausea, vomiting, chest discomfort, and palpitations may occur, and immediate discontinuation should be done if symptoms arise. Rapid administration in large amounts may cause acidosis, so caution is warranted. This medication may also cause serious side effects such as chills, fever, headache, and respiratory distress, so if unusual symptoms occur, patients should consult healthcare professionals immediately. If magnesium is included, peripheral vasodilation may occur, requiring caution. Various metabolic abnormalities, including metabolic acidosis, hypophosphatemia, and hyperglycemia, may arise, necessitating regular testing. Patients with impaired liver or kidney functions should be cautious as blood urea nitrogen levels may increase. Safety has not been established during pregnancy, hence it should only be used when therapeutic benefits outweigh the risks. When administered to children, maintain a lower concentration and frequently check blood ammonia levels. Elderly patients may have reduced body functions, so administration speed should be slow, and dosages should be adjusted. As this medication contains electrolytes, caution is needed regarding electrolyte balance during large doses, and rapid infusion may cause side effects, necessitating slow administration. Strict aseptic conditions must be maintained during administration, and discolored or cloudy solutions should not be used. During storage, the package should not be opened, and products with damaged rubber stoppers should not be used.

Serious side effects

Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pallor, severe allergic reactions, severe rashes, blisters, skin peeling, pain in oral/ocular mucosa, severe skin adverse reactions, difficulty breathing, asthma attacks, cough with fever accompanying respiratory abnormalities, yellowing of the skin or eyes (jaundice), severe lethargy, hepatic abnormalities, severe edema, or urinary abnormalities (decreased urine output, generalized severe edema, blood pressure changes).

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• tachycardia
• hypertension
• chills
• fever
• headache

This medication should be stored in a sealed container to prevent exposure to air and is best kept at room temperature between 1 to 30 degrees Celsius. This helps to maintain the efficacy of the medication.

Appearance

A colorless to pale yellow transparent injection solution in a plastic container for infusion.

Package unit

100mL/bag, 250mL/bag